Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by SamV21on May 18, 2022 1:23am
209 Views
Post# 34691349

Shareholders did their part ,Buying shares on Guy promises!

Shareholders did their part ,Buying shares on Guy promises!

Tetra told investors it is moving ahead with a plan to launch its TERPACAN products in Canadian pharmacy retail locations by mid-2020.

 

After receiving two drug identification numbers from Health Canada last week, Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) is now looking to get its products to market within this calendar year.

On Monday (January 20), the Canadian maker of cannabinoid-based drugs told investors that, with the two over-the-counter identification numbers for its TERPACAN brand of hemorrhoid and back and muscle pain treatments, it is moving ahead with its plan to launch the products in Canadian pharmacy retail locations by mid-2020.
WELL GUY WHERE IS OUR MONEY ??? 


<< Previous
Bullboard Posts
Next >>